{"analyses":[{"groupDescription":"Week 5","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.41","pValueComment":"One-sided significance level 0.05","statisticalMethod":"t-test, 1 sided"},{"groupDescription":"Week 5","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.35","pValueComment":"One-sided significance level 0.05","statisticalMethod":"t-test, 1 sided"},{"groupDescription":"Week 9","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.83","pValueComment":"One-sided significance level 0.05","statisticalMethod":"t-test, 1 sided"},{"groupDescription":"Week 9","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.79","pValueComment":"One-sided significance level 0.05","statisticalMethod":"t-test, 1 sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.84","value":"3.84"},{"groupId":"OG001","spread":"6.08","value":"4.01"},{"groupId":"OG002","spread":"7.48","value":"3.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"61"}],"units":"Participants"}],"title":"Week 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.66","value":"3.29"},{"groupId":"OG001","spread":"6.63","value":"3.55"},{"groupId":"OG002","spread":"8.36","value":"4.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"60"}],"units":"Participants"}],"title":"Week 9"}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"77"}],"units":"Participants"}],"description":"The FSFI total score measures self-reported female sexual functioning covering the major domains arousal, satisfaction, and orgasm, and including lubrication and pain. Possible scores range from 2 to 36, with higher scores indicating better functioning. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased functioning. This measure is referred to as \"sexual functioning\" in the protocol.","dispersionType":"Standard Error","groups":[{"description":"One Bupropion 150 mg XL capsule PO in a.m. daily for one week; one Bupropion 150 mg XL capsule and one placebo capsule PO in a.m. daily for 8 weeks; one placebo capsule daily PO in a.m. for one 1 week (titration off).","id":"OG000","title":"Bupropion 150 mg"},{"description":"One Bupropion 150 mg XL capsule PO in a.m. daily for one week; two Bupropion 150 mg XL capsules PO in a.m. daily for 8 weeks (300 mg target dose); one Bupropion 150 mg XL capsule PO in a.m. daily for 1 week (titration off)","id":"OG001","title":"Bupropion 300 mg"},{"description":"One placebo capsule PO in a.m. daily for 1 week; two placebo capsules PO in a.m. daily for 8 weeks; one placebo capsule PO in a.m. daily for 1 week (titration off)","id":"OG002","title":"Placebo"}],"paramType":"MEAN","populationDescription":"Eligible with baseline data","reportingStatus":"POSTED","timeFrame":"Baseline (prior to randomization) and 5 and 9 weeks from start of treatment (within 21 days of randomization)","title":"Change From Baseline in FSFI Total Score (\"Sexual Functioning\")","type":"SECONDARY","unitOfMeasure":"units on a scale"}